The Trump Administration took another step earlier this month to help lower drug prices by proposing a new regulation that would require drug makers to include a medication’s list price in direct-to-consumer (DTC) advertisements. Despite the fact that this proposal has strong support from the American public and bipartisan members of Congress, it has unsurprisingly […]
Through the advancement of modern medicine, biologic drugs are providing new hope that patients will be able to treat – and in many cases overcome – diseases that traditional medications could not. Unfortunately, until the U.S. Food and Drug Administration (FDA) finalizes guidance that would encourage more affordable biologic options, these life-saving drugs will be […]
“CAPG’s physicians experience the impact high prescription drug prices have on patients every day,” said CSRxP Executive Director John Rother. “When people cannot afford their medications because of the costly price tag, it’s harder to get and stay healthy. For CAPG physicians and their patients, prescription drug pricing is personal.”
“ACHP’s expertise as a national leader in tackling health care challenges is invaluable and we are glad to have them on board,” said CSRxP Executive Director John Rother. “Patient-centered community health systems work with families struggling every day to afford costly prescription drugs, and those medications are only getting more expensive.”
“Patients with chronic conditions, such as Hepatitis C, benefit immensely when breakthrough, life-changing drugs provide a cure where none existed before. But when states are driven to create access limitations to that same drug for their Medicaid populations, we have to acknowledge something is not quite right here.”
Members of the Campaign for Sustainable Rx Pricing (CSRxP) gathered on Capitol Hill to discuss market-based policy solutions to curb rising drug prices.
Our new board game illustrates how pharmaceutical companies have a monopoly on the current pricing system and the different ways they keep prices high.
“With this provision, policymakers are rewriting the rules to benefit pharmaceutical manufacturers for slightly tweaking their product and reintroducing it as a new ‘innovation,’” CSRxP Executive Director John Rother said.
“Prescription drug costs are rising much faster than other parts of Medicare and putting ever greater financial pressure on the program and on its beneficiaries. It’s no wonder that voters are making prescription drug prices a top issue in this election.”
The Campaign for Sustainable Rx Pricing (CSRxP) announced its endorsement of the Creating and Restoring Equal Access to Equivalent Samples (“CREATES”) Act, a bill introduced today in the Unites States Senate.